Initial Orders Include the Recently Patented MicroPulse® P3 Disposable Probe

Mountain View, Calif., March 17, 2015 —IRIDEX Corporation (Nasdaq:IRIX) announced the first commercial sales of its new Cyclo G6 laser system, designed to treat patients diagnosed with a range of glaucoma disease states. The Cyclo G6 system includes a glaucoma dedicated laser along with a family of single use probes, including the newly patented MicroPulse P3 disposable.

Glaucoma is an eye disease that causes damage to the optic nerve, which carries images from the retina to the brain. In glaucoma, heightened eye pressure can lead to progressive damage of the delicate nerve fibers of the optic nerve. The Cyclo G6 offers repeatable and minimally invasive approaches to slowing the progress of the disease.

“Glaucoma is a chronic disease that requires careful management to preserve a patient’s vision long term,” stated glaucoma and cataract specialist Robert Noecker, MD of the Ophthalmic Consultants of Connecticut. “The procedure performed with the new MicroPulse P3 disposable demonstrated safety and clinical efficacy without the need for incisional surgery.”

The market debut of this system was announced at the recent American Glaucoma Society (AGS) congress. IRIDEX had a particularly strong presence at the AGS meeting that included multiple scientific poster presentations regarding the safety and efficacy of the MicroPulse P3 disposable. The Company hosted daily surgical training labs, which concluded with multiple orders taken.

“At the AGS there was a poster from Mexico that presented that costs of glaucoma treatments may represent upwards of 40 percent of a patient’s household income,” stated Will Moore, IRIDEX President and CEO. “Cost and logistics prohibit the required care for many of these patients, leading to very low rates of compliance and the continual progression towards blindness. To address this situation, we continue to pursue clinically durable and cost effective solutions such as MicroPulse treatment, to address this large and growing patient population.”

Glaucoma is the leading cause of adult irreversible blindness. It is estimated that more than 4 million people in the US and approximately 60 million worldwide are afflicted with glaucoma today.

About IRIDEX

IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. IRIDEX is dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 70 independent distributors into over 100 countries. For further information, visit the IRIDEX website at http://www.iridex.com/.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including those statements concerning the markets in which the Company operates, trends in treatment and product usage, product plans and future product releases, regulatory approvals, usage and efficacy of Company products, future financial results and the Company’s strategic plans and objectives. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended December 28, 2013, which was filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.